 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AMG 329 / Amgen
Trial primary completion date: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (clinicaltrials.gov) - Aug 1, 2024
P2, N=262, Recruiting, Sponsor: Amgen
Trial primary completion date: Sep 2026 --> Jun 2026
- |||| AMG 329 / Amgen
Enrollment open: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (clinicaltrials.gov) - Apr 29, 2024
P2, N=262, Recruiting, Sponsor: Horizon Therapeutics Ireland DAC
Trial primary completion date: Sep 2026 --> Jun 2026 Not yet recruiting --> Recruiting
- ||||| AMG 329 / Amgen
New P2 trial: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (clinicaltrials.gov) - Mar 14, 2024
P2, N=262, Not yet recruiting, Sponsor: Horizon Therapeutics Ireland DAC
- ||| AMG 329 / Amgen
Trial completion, Trial completion date, Trial primary completion date: VIB1116.P1.S1: A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (clinicaltrials.gov) - Aug 2, 2023
P1, N=73, Completed, Sponsor: Viela Bio (acquired by Horizon Therapeutics)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023
- || AMG 329 / Amgen
Trial completion date, Trial primary completion date: VIB1116.P1.S1: A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (clinicaltrials.gov) - Mar 10, 2023
P1, N=73, Active, not recruiting, Sponsor: Viela Bio (acquired by Horizon Therapeutics)
Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> Jul 2023 Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: May 2023 --> Nov 2023
- || AMG 329 / Amgen
Enrollment closed: VIB1116.P1.S1: A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (clinicaltrials.gov) - Dec 15, 2022
P1, N=73, Active, not recruiting, Sponsor: Viela Bio (acquired by Horizon Therapeutics)
Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: May 2023 --> Nov 2023 Recruiting --> Active, not recruiting
- || AMG 329 / Amgen
Trial completion date, Trial primary completion date: VIB1116.P1.S1: A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (clinicaltrials.gov) - Apr 22, 2022
P1, N=72, Recruiting, Sponsor: Viela Bio (acquired by Horizon Therapeutics)
Recruiting --> Active, not recruiting Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Sep 2022 --> May 2023
- ||| AMG 329 / Amgen
New P1 trial: VIB1116.P1.S1: A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (clinicaltrials.gov) - Jun 30, 2021
P1, N=60, Recruiting, Sponsor: Viela Bio